Tuesday, July 14, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Jul 13, 2026
FDA releases 14 new drug rejection letters after 3-month pause in transparency policy
background ▾
- •FDA's CRL transparency policy was paused for three months following industry pushback but has now resumed, with 14 letters released including rejections for Grace Therapeutics' nimodipine and Hengrui/Elevar's PD-1/VEGFR combo
- •Undisclosed pharma company challenged the policy via citizen petition, citing concerns over confidential commercial information redaction and lack of sponsor involvement in disclosure timing
- •Formal rulemaking and Congressional amendments proposed by ex-Commissioner Makary remain in progress, creating regulatory uncertainty around the long-term scope and implementation of CRL disclosures
Grace TherapeuticsHengrui PharmaElevar Therapeuticsnimodipine (injectable)anti-PD-1/VEGFR combination
→ Read original articlePolicy•KFF•Jul 14, 2026
The AI Arms Race in Administrative Health Care
background ▾
- •Providers and insurers are engaged in a parallel AI deployment race focused on administrative functions (billing, prior authorization, denial review) rather than clinical outcomes, with unclear implications for overall healthcare spending reduction.
- •Independent evaluations suggest AI in healthcare administration may accelerate existing cost-control conflicts rather than achieve systemic savings, raising questions about whether technology solves fundamental incentive misalignment.
- •Monitor whether regulatory or policy interventions emerge to align AI deployment incentives toward genuine cost reduction and care quality rather than zero-sum revenue capture/denial strategies.
Peterson Health Technology Institute
→ Read original articlePolicy•STAT News•Jul 14, 2026
FDA authorized Zyn nicotine pouches without knowing what they were made of, says former agency scientist
background ▾
- •FDA approved Zyn without formally characterizing or assessing the composition and potential health impacts of the pouch material itself, contrary to regulatory requirements that all product components be evaluated.
- •An internal FDA scientist documented concerns about microplastic exposure and material integrity that were allegedly ignored, and was incorrectly credited with approving an environmental review she did not sign off on.
- •This approval gap may trigger regulatory review, congressional scrutiny, or legal challenges given the rapidly growing $6.8 billion U.S. nicotine pouch market and emerging evidence linking microplastics to organ accumulation and potential harm.
Philip Morris InternationalZyn
→ Read original articlePolicy•STAT News•Jul 14, 2026
12 ideas for tackling the U.S. alcohol epidemic
background ▾
- •Alcohol screening effectiveness is comparable to blood pressure checks and flu vaccines, yet remains inconsistent and underutilized in U.S. primary care—a low-cost intervention with high preventive potential.
- •Industry influence and fragmented state-level regulation have prevented meaningful policy progress on alcohol control for nearly a century, with the Trump administration now seeking expert recommendations on the issue.
- •Specific high-risk populations (pregnant women, metabolic disease patients, adolescents) are systematically under-screened and under-treated, requiring targeted clinical and public health interventions.
Policy•STAT News•Jul 14, 2026
Opinion: It looks like your doctor and talks like your doctor. But it’s not your doctor
background ▾
- •Deepfakes of real physicians are already being deployed at scale to endorse unregulated supplements and dubious treatments on major platforms, exploiting the visual and vocal cues patients trust.
- •Deepfakes threaten three layers of digital medicine trust: identity (who is speaking), clinical records (EHR tampering and voice-cloned commands), and evidence integrity (synthetic clinical trial data indistinguishable from real results).
- •Urgent need for regulatory frameworks, authentication standards, and platform governance to address this emerging threat before deepfake-assisted medical fraud becomes widespread and costly to unwind.
Market Access
Market Access•Fierce Biotech•Jul 14, 2026
Spero pivots to I&I with $1.1B deal for Innovent antibody, sells slice of Utebzi royalties for $105M
background ▾
- •Spero acquires global rights (ex-China) to SP001, a CD40L antibody with phase 1b data in Sjögren's disease, planning phase 2 development in IgG4-RD—a deliberate therapeutic pivot enabled by Utebzi's recent FDA approval
- •The $105 million royalty monetization deal with HCRx provides immediate capital for SP001 development while allowing HCRx to capture 65% of Utebzi profits post-repayment—a novel financing structure for early-stage I&I indications
- •Watch for: SP001 phase 2 data readout timeline in IgG4-RD and parallel Innovent phase 2b initiation in China for Sjögren's; broader indication expansion strategy; and commercial performance of Utebzi against GSK's commercialization execution
Spero TherapeuticsInnovent BiologicsHealthcare RoyaltySP001IBI355Utebzi
→ Read original articleMarket Access•Fierce Biotech•Jul 14, 2026
Avere goes public via NextCure reverse merger, secures Hansoh IL-23 drug with $2.3B deal
background ▾
- •Avere enters public markets with immediate lead asset and substantial capital ($320M placement) to fund phase 2b/3 development of AVR-001, a weekly oral IL-23 inhibitor
- •AVR-001 early phase 1b data in China showed efficacy comparable to daily oral inhibitors, but the drug faces a saturated psoriasis market with entrenched competition from BMS, J&J, and other oral IL-23 programs
- •Clinical and commercial execution will be critical—phase 2b psoriasis readout (1H 2028) will determine whether weekly dosing justifies premium positioning; Avere's leadership previously scaled Akero to Novo acquisition, suggesting operational competence
Avere TherapeuticsNextCureHansoh PharmaceuticalAVR-001SkyriziTremfya
→ Read original articleMarket Access•Endpoints News•Jul 14, 2026
Former Akero team announces new I&I company, Avere, with China drug
background ▾
- •Ex-Akero leadership establishing new I&I biotech company, signaling continued entrepreneurship despite Akero's setbacks in metabolic disease
Akero TherapeuticsAvere
→ Read original articleMarket Access•Endpoints News•Jul 13, 2026
Health tech funding rises to $7.4B in the first half of 2026
background ▾
- •Digital health venture funding increased 15% year-over-year to $7.4B in H1 2026, signaling sustained investor appetite for health tech despite broader biotech funding volatility
Market Access•Endpoints News•Jul 13, 2026
Busy M&A activity sets tone as biopharma earnings season kicks off
background ▾
- •M&A activity is elevated as biopharma enters earnings season, signaling potential strategic consolidation or portfolio reshuffling across the sector
Clinical Trials
Clinical Trials•Fierce Biotech•Jul 13, 2026
Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors
background ▾
- •Bempikibart achieved 30.3% SALT-20 response rate (40% in modified ITT analysis) and 33.3% SALT-50 response at 36 weeks with excellent tolerability and early durability signals, supporting advancement to registration-directed trials
- •Q32 plans registration trial initiation in H1 2027; clinical competitiveness versus entrenched JAK inhibitors will depend on comparative efficacy, durability, and safety data in larger, adequately-powered studies
- •Watch for registration trial design, enrollment progress, and durability follow-up data; potential competitive positioning if bempikibart demonstrates sustained remission off-drug versus JAK inhibitor relapse patterns
Q32 BioEli LillyIncytebempikibartOlumiantLitfulo
→ Read original articleClinical Trials•Fierce Biotech•Jul 13, 2026
Agenus scraps phase 3 colorectal study after 3 months to narrow focus to colon cancer
background ▾
- •Agenus abandoned Battman after 3 months despite claims of 'unprecedented investigator and patient enthusiasm,' suggesting significant enrollment or strategic challenges in the metastatic setting
- •The company is refocusing on neoadjuvant/perioperative colon cancer (stage II/III MSS), a 'cold tumor' indication where checkpoint inhibitors have historically underperformed, with an estimated $7 billion U.S. market opportunity
- •Watch for Robbin enrollment trajectory and safety/efficacy signals in early-stage disease, especially given prior phase 2 failure of BOT+BAL+agenT-797 in gastroesophageal cancer; competitive landscape in MSS colon cancer intensifying with other immunotherapy combinations
AgenusCommodore CapitalRA Capital ManagementbotensilimabbalstilimabagenT-797
→ Read original article